|
TP53 mutation and abnormal p53 expression in endometrial cancer: Associations with race and outcomes
|
September 25, 2023
|
PC3I Authors Emily Ko |
Gynecologic Oncology
|
|
Role of immunotherapy for lymph node positive vulvar melanoma: utilization and outcomes
|
September 4, 2023
|
PC3I Authors Emily Ko |
International Journal of Gynecological Cancer
|
|
Telehealth utilization in gynecologic oncology clinical trials
|
September 2, 2023
|
PC3I Authors Emily Ko; Emily Gleason |
Gynecologic Oncology
|
|
Racial disparities in receipt of radiation and brachytherapy in cervical cancer patients and impact on survival outcomes: Do they exist in a SEER-Medicare population? (2124)
|
September 1, 2023
|
PC3I Authors Emily Gleason; Emily Ko |
Gynecologic Oncology
|
|
Next generation sequencing reveals a high prevalence of pathogenic mutations in homologous recombination DNA damage repair genes among patients with uterine sarcoma
|
August 23, 2023
|
PC3I Authors Emily Ko |
Gynecologic Oncology
|
|
Insurance status and time to radiation care after pathologic diagnosis for cervical cancer patients
|
July 3, 2023
|
PC3I Authors Anna Jo Smith; Emily Ko |
Gynecologic Oncology Reports
|
|
Disparities in clinical trial participation in ovarian cancer: A real-world analysis
|
June 10, 2023
|
PC3I Authors Anna Jo Smith; Emily Ko |
Gynecologic Oncology
|
|
Cost of care associated with utilization of telehealth in clinical trials.
|
May 31, 2023
|
PC3I Authors Emily Gleason; Emily Ko |
Journal of Clinical Oncology
|
|
Insurance and racial disparities in prior authorization in gynecologic oncology
|
March 21, 2023
|
PC3I Authors Anna Jo Smith; Lakeisha Mulugeta-Gordon; Justin Bekelman; Emily Ko |
Gynecologic Oncology Reports
|
|
Facility level variation in the utilization of neoadjuvant chemotherapy is associated with higher surgical morbidity for patients with advanced stage epithelial ovarian carcinoma
|
December 12, 2022
|
PC3I Authors Emily Ko |
Gynecologic Oncology
|
|
Prior authorization in gynecologic oncology: An analysis of clinical impact
|
October 16, 2022
|
PC3I Authors Anna Jo Smith; Lakeisha Mulugeta-Gordon; Justin Bekelman; Emily Ko |
Gynecologic Oncology
|
|
Predictive value of 5-Factor modified frailty index in Oncologic and benign hysterectomies
|
September 2, 2022
|
PC3I Authors Emily Ko |
Gynecologic Oncology Reports
|
|
Disparities in biomarker testing in ovarian cancer: a real-world analysis
|
August 25, 2022
|
PC3I Authors Anna Jo Smith; Emily Ko |
American Journal of Obstetrics and Gynecology
|
|
Addition of External Beam Radiation Therapy to Adjuvant Chemotherapy for Patients With Stage IIIC Uterine Endometrioid Carcinoma: Utilization and Outcomes
|
August 4, 2022
|
PC3I Authors Emily Ko |
American Journal of Clinical Oncology
|
|
Safety of ovarian preservation for premenopausal patients with FIGO stage I grade 2 and 3 endometrioid endometrial adenocarcinoma
|
July 26, 2022
|
PC3I Authors Emily Ko |
International Journal of Gynecological Cancer
|
|
Oncologic outcomes of surgical para-aortic lymph node staging in patients with advanced cervical carcinoma undergoing chemoradiation
|
July 5, 2022
|
PC3I Authors Emily Ko |
International Journal of Gynecological Cancer
|
|
An evaluation of the microbiota of the upper reproductive tract of women with and without epithelial ovarian cancer
|
June 27, 2022
|
PC3I Authors Emily Ko |
Gynecologic Oncology Reports
|
|
Delay in adjuvant chemotherapy administration for patients with FIGO stage I epithelial ovarian carcinoma is associated with worse survival; an analysis of the National Cancer Database
|
June 6, 2022
|
PC3I Authors Emily Ko |
Gynecologic Oncology
|
|
Adjuvant chemotherapy for stage I high-intermediate risk endometrial carcinoma with lymph-vascular invasion
|
June 1, 2022
|
PC3I Authors Emily Ko |
International Journal of Gynecological Cancer
|
|
The frequency and persistence of lymphedema diagnosis and self-reported symptoms over 5 years in patients with endometrial carcinoma
|
May 20, 2022
|
PC3I Authors Emily Ko |
Gynecologic Oncology Reports
|
